Advanced Proteome Therapeutics (STU:0E81) Days Payable: 0.00 (As of Apr. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Advanced Proteome Therapeutics Days Payable?

Advanced Proteome Therapeutics STU:0E81 Days Payable is 0.00 as of Apr. 2023.

Advanced Proteome Therapeutics's average Accounts Payable for the three months ended in Apr. 2023 was €0.36 Mil. Advanced Proteome Therapeutics's Cost of Goods Sold for the three months ended in Apr. 2023 was €0.00 Mil.

The historical rank and industry rank for Advanced Proteome Therapeutics's Days Payable or its related term are showing as below:

STU:0E81's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 112.84
* Ranked among companies with meaningful Days Payable only.

Advanced Proteome Therapeutics's Days Payable stayed the same from Apr. 2022 (0.00) to Apr. 2023 (0.00). stayed the same

Advanced Proteome Therapeutics Days Payable Historical Data

* Premium members only.

The historical data trend for Advanced Proteome Therapeutics's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Advanced Proteome Therapeutics Days Payable Chart

Advanced Proteome Therapeutics Annual Data
Trend Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22
Days Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Advanced Proteome Therapeutics Quarterly Data
Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23
Days Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

STU:0E81 vs VRTX, REGN, SGEN: Days Payable Comparison

For the Biotechnology subindustry, Advanced Proteome Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Advanced Proteome Therapeutics Days Payable vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Advanced Proteome Therapeutics's Days Payable distribution charts can be found below:

* The bar in red indicates where Advanced Proteome Therapeutics's Days Payable falls into.


Advanced Proteome Therapeutics Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Advanced Proteome Therapeutics's Days Payable for the fiscal year that ended in Jul. 2022 is calculated as

Days Payable (A: Jul. 2022 )
=Average Accounts Payable /Cost of Goods Sold*Days in Period
=( (Accounts Payable (A: Jul. 2021 ) + Accounts Payable (A: Jul. 2022 )) / count ) / Cost of Goods Sold (A: Jul. 2022 )*Days in Period
=( (0.491 + 0.654) / 2 ) / 0*365
=0.5725 / 0*365
=N/A

Advanced Proteome Therapeutics's Days Payable for the quarter that ended in Apr. 2023 is calculated as:

Days Payable (Q: Apr. 2023 )
=Average Accounts Payable / Cost of Goods Sold*Days in Period
=( (Accounts Payable (Q: Jan. 2023 ) + Accounts Payable (Q: Apr. 2023 )) / count ) / Cost of Goods Sold (Q: Apr. 2023 )*Days in Period
=( (0.661 + 0.049) / 2 ) / 0*365 / 4
=0.355 / 0*365 / 4
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Days Payable →
What does a Days Payable of 0.00 mean?
Advanced Proteome Therapeutics (STU:0E81) has a Days Payable of 0.00 as of Apr. 2023. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Advanced Proteome Therapeutics and its competitors.
Is Advanced Proteome Therapeutics' Days Payable too high?
Advanced Proteome Therapeutics' current Days Payable is 0.00.
How does Advanced Proteome Therapeutics' Days Payable compare to VRTX and REGN?
Advanced Proteome Therapeutics' Days Payable of 0.00 can be compared against companies in the Biotechnology industry. The industry median Days Payable is 112.84. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 703 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Advanced Proteome Therapeutics and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Advanced Proteome Therapeutics's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Advanced Proteome Therapeutics stock overvalued right now?
Advanced Proteome Therapeutics (STU:0E81) has a current Days Payable of 0.00. The current Days Payable is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Advanced Proteome Therapeutics (STU:0E81), the current Days Payable is 0.00 as of Apr. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Advanced Proteome Therapeutics Business Description

Address 104 8337 Eastlake Drive, Burnaby, BC, CAN, V5A 4W2
Advanced Proteome Therapeutics Corp is a biotechnology company. It develops and commercializes a platform to use protein modification technologies to create proprietary human protein pharmaceuticals with therapeutic properties. The company develops anti-cancer drugs for cancerous tumors that will destroy a cancer patient's tumor cells selectively, sparing healthy cells. All the operations of the organization are principally carried out in the United States.